Financial Performance - Revenue increased by 8% to $168 million in 1Q 2025[31, 35] - Clinical NGS revenue grew by 18%[17, 19] - Adjusted Gross Profit increased by 11% to $79 million[31] - Adjusted EBITDA improved by 102% to $7 million[15, 31] - Adjusted Gross Margin increased to 47%, a 146 bps improvement[17, 32] Operational Highlights - Clinical volume increased by 8% year-over-year, reaching 326,000 units[12, 31] - The company announced the acquisition of Pathline to strengthen its commercial presence in the Northeast[17, 25] - Clinical revenue per test improved by 3% due to mix and pricing[13, 35] Strategic Initiatives - The company submitted PanTracer LBx to MolDx[17, 42] - The company is expanding its salesforce up to 140 representatives[23] Financial Guidance - The company revised its full-year 2025 revenue guidance to $747-$759 million, representing a 13-15% year-over-year growth[38] - The company reiterated its full-year adjusted EBITDA guidance of $55-$58 million, representing a 38-45% year-over-year growth[38]